Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
News & Analysis: Genomic Health
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
The genetic testing industry is still in its infancy, but this leader is comfortably profitable and growing at a healthy clip.
A good start to the year and no increased guidance mean slower growth ahead.
After Genomic's stellar first quarter, investors are getting jittery about growth in the second half.
GHDX earnings call for the period ending March 31, 2019.
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Find out how these companies have positioned themselves for bigger gains.
The cancer test maker is growing earnings much faster than revenue.
GHDX earnings call for the period ending December 31, 2018.